Literature DB >> 17684355

Push/pull hemodiafiltration.

Toru Shinzato1, Kenji Maeda.   

Abstract

Push/pull hemodiafiltration is characterized by alternate filtration and backfiltration, while sterile pyrogen-free dialysate is flowing through a hemodiafilter. During the filtration phase, uremic substances are eliminated not only by diffusive, but also by convective transport. During the backfiltration phase, dialysate is quickly pushed to the blood side (i.e. backfiltration) so as to make up for the excessive reduction in body fluid that has developed during the immediately preceding filtration phase. In the most recently improved version of push/pull hemodiafiltration, the body fluid replacement volume is over 120 liters during a 4- hour treatment. This replacement of a large amount of body fluid may be due to the increased filtration rate in the hemodiafilter resulting from failure of the complete formation of a protein gel layer on the blood side surface. The filtration time in push/pull hemodiafiltration is so short that the also short backfiltration to follow may take over before the protein gel layer is completely formed on the membrane surface. Since the filtration and backfiltration times are much shorter in push/pull hemodiafiltration than the time for blood to pass through the hemodiafilter, it is concentrated and diluted many times (approx. 25 times) before it leaves the hemodiafilter. Therefore, push/pull hemodiafiltration is functionally similar to a predilution hemodiafiltration. The reduction rate of beta-microglobulin was greater by push/pull hemodiafiltration than by hemodialysis, when a high-flux polysulfone hemodiafilter was employed. However, the difference in the reduction rate was rather small between them, because of the improved hemodiafilters, which remove so much beta2-microglobulin only by dialysis. Nevertheless, restless legs syndrome, irritability, insomnia and pruritus were alleviated after switching the treatment modality from hemodialysis to push/pull hemodiafiltration. This may indicate that these symptoms are caused by the accumulation of uremic substances larger than beta2-microglobulin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684355     DOI: 10.1159/000107247

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  5 in total

1.  Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease.

Authors:  Takuya Wakamatsu; Suguru Yamamoto; Kenya Kamimura; Takeshi Nakatsue; Noriaki Iino; Seitaro Iguchi; Yoshikatsu Kaneko; Shin Goto; Junichiro James Kazama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2015-12-11

Review 2.  Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine.

Authors:  Bernard Canaud; Stefano Stuard; Frank Laukhuf; Grace Yan; Maria Ines Gomez Canabal; Paik Seong Lim; Michael A Kraus
Journal:  Clin Kidney J       Date:  2021-12-27

3.  An experimental and numerical study of the flow and mass transfer in a model of the wearable artificial kidney dialyzer.

Authors:  Edmond Rambod; Masoud Beizai; Moshe Rosenfeld
Journal:  Biomed Eng Online       Date:  2010-05-24       Impact factor: 2.819

4.  Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus.

Authors:  Wen-Hong Li; Yu-Min Yin; Hao Chen; Xiao-Dan Wang; He Yun; Hui Li; Jie Luo; Jin-Wen Wang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Therapeutic effect of high-efficiency online hemodiafiltration for recurrent restless legs syndrome in dialysis patients.

Authors:  Kenji Sakurai; Takeshi Saito; Hiromi Hosoya; Yoshitaka Kurihara; Fumi Yamauchi
Journal:  J Artif Organs       Date:  2020-03-30       Impact factor: 1.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.